KalVista Pharmaceuticals, Inc. logo KALV - KalVista Pharmaceuticals, Inc.

Inactive Ticker KALV is not actively trading. Quotes and analytics may be stale.
Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 11
HOLD 2
SELL 0
STRONG
SELL 0
| PRICE TARGET: $28.67 DETAILS
HIGH: $32.00
LOW: $27.00
MEDIAN: $27.00
CONSENSUS: $28.67
UPSIDE: 6.19%

Stock News

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

PARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition of KalVista Pharmaceuticals, Inc. (“KalVista”). KalVista is now part of Chiesi Group and will contribute to the growth of the Rare Diseases business unit, focused on research, development and commercialization of therapies for rare and ultra-rare conditions. With the completion of the transac.

Jun 11, 2026 04:41 AM • businesswire.com
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben Palleiko, Chief Executive Officer of KalVista. “Currentl.

May 28, 2026 03:00 AM • businesswire.com
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) to Chiesi Group. Under the terms of the proposed transaction, shareholders of KalVista will receive $27.00 in cash for each share of KalVista that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequ.

May 19, 2026 10:11 AM • businesswire.com (Hide legal announcements)
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) to Chiesi Group. Under the terms of the proposed transaction, shareholders of KalVista will receive $27.00 in cash for each share of KalVista that they own. KSF is seeking to determine whether this consideration and the process that led to it are.

May 01, 2026 08:30 AM • businesswire.com (Hide legal announcements)
Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE, April 29, 2026 /PRNewswire/ -- Ademi LLP is investigating KalVista (NASDAQ: KALV) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Chiesi Group. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

Apr 29, 2026 08:17 AM • prnewswire.com (Hide legal announcements)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV)

NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating KalVista Pharmaceuticals, Inc. (NASDAQ:  KALV ) related to its sale to Chiesi Group. Under the terms of the proposed transaction, KalVista shareholders are expected to receive $27.00 per share in cash. Is it a fair deal?

Apr 29, 2026 07:01 AM • globenewswire.com (Hide legal announcements)
KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) to Chiesi Group for $27.00 per share in cash. Halper Sadeh encourages KalVista shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether KalVista and its board of directors.

Apr 29, 2026 06:17 AM • businesswire.com
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

PARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc. (“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi's and KalVista's Boards of Directors and is expected to close in Q3 2026, subject to.

Apr 29, 2026 03:42 AM • businesswire.com
KalVista Pharmaceuticals Touts EKTERLY Launch: Nearly $50M in Under 6 Months, 20% Patient Reach

KalVista Pharmaceuticals Touts EKTERLY Launch: Nearly $50M in Under 6 Months, 20% Patient Reach

KalVista Pharmaceuticals (NASDAQ: KALV) CEO Ben Palleiko told investors at Needham and Company's 25th Annual Healthcare Conference that the company has seen a strong early commercial launch for EKTERLY, which he described as the "first and only oral on-demand therapy for treatment of HAE attacks." Palleiko said the company launched EKTERLY immediately after FDA approval last

Apr 17, 2026 09:05 PM • defenseworld.net

Price Targets